Technology | Computed Tomography (CT) | November 26, 2017

Samsung Unveils Mobile CT OmniTom at RSNA 2017

Mobile 16-slice scanner sports omni-directional wheels for easier mobility; company also highlights DR, ultrasound and MRI technologies

Samsung Unveils Mobile CT OmniTom at RSNA 2017

November 26, 2017 — Samsung Electronics debuted its OmniTom mobile 16-slice computed tomography (CT) scanner at the Radiological Society of North America (RSNA) 2017 Annual Meeting, Nov. 26-Dec. 1 in Chicago. OmniTom received 510(k) U.S. Food and Drug Administration (FDA) clearance for the U.S. market on Aug. 18 of this year.

OmniTom features an array of improvements from Samsung's CereTom CT scanner, including:

  • Improved workflow: According to Samsung, OmniTom is the world's first mobile imaging device with omni-directional wheels, maximizing mobility and allowing easier and quieter movement in small spaces;
  • Superior image quality: Sixteen-slice (0.625 mm per slice) advanced data acquisition system with effective dose optimization;
  • Expanded use: Maintains a small footprint ideal for mobile use while increasing the gantry opening to 40 cm for improved coverage of adult head and neck, and full body pediatric scanning; and
  • Enhanced safety system: OmniTom features an internal drive system, making portability less strenuous, while also offering smart-sensing collision avoidance software to maximize control and patient safety.

OmniTom is ideal for cranial procedures and is designed to deliver high-quality non-contrast CT, CT angiography and CT perfusion scans. The combination of its rapid scan time, ultra-small footprint and immediate image viewing helps OmniTom collect real-time data on critically ill patients.

The latest product also demonstrates Samsung's "AccE" (Access, Accuracy and Efficiency) to incorporate innovations in physical access to provide care wherever it is needed. It also aims to improve accuracy in diagnosis with advanced algorithms and efficiency with advanced display, UX and information management technology developed by Samsung Electronics.

In addition to OmniTom, Samsung will be showcasing its spectral CT with Photon Counting Detector (PCD), the next generation of CT technology. Samsung's team will also be demonstrating a range of healthcare solutions in mobile CT, digital radiography and ultrasound that are all designed to bridge the care-delivery gap and maximize efficiency to enhance the patient experience. Such solutions include:

  • Ultrasound Segment: Samsung will feature their comprehensive general imaging ultrasound portfolio, including the new HS60 and HS40 ultrasound systems that were introduced earlier this year. The RS80A with Prestige, Samsung's premium general imaging ultrasound system, will be displayed in three daily educational demonstrations featuring live scanning. The RS80A includes technologies for the busy radiology department that help boost clinical confidence;
  • Digital Radiography Segment: Samsung will display a wide range of its portfolio including two ceiling-mounted systems, GC85 and GC70, as well as highlight its premium portable GM85 X-ray. The GM85's enhanced mobility and streamlined workflow will enable users to experience high efficiency and image quality. Samsung has also adopted low-dose technology for enhanced patient safety; and
  • Magnetic Resonance Imaging Segment: Samsung will be showcasing a prototype of specialty MRI, an MRI imaging device for arms and/or legs. It is designed to maximize not only cost and space but also patient convenience, as it eliminates the need for the whole body to be in the MRI device.

For more information: www.samsung.com

 

Related Content

The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
According to an inquest, a man with a heart disorder and chest pain died two days after a doctor viewed the wrong scan and sent him home
News | Computed Tomography (CT) | October 21, 2020
October 21, 2020 — The BBC News
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea